Skip to main content
Erschienen in: Familial Cancer 1/2013

01.03.2013 | Original Article

Psychosocial factors and uptake of risk-reducing salpingo-oophorectomy in women at high risk for ovarian cancer

verfasst von: Bettina Meiser, Melanie A. Price, Phyllis N. Butow, Janan Karatas, Judy Wilson, Louise Heiniger, Brandi Baylock, Margaret Charles, Sue-Anne McLachlan, Kelly-Anne Phillips

Erschienen in: Familial Cancer | Ausgabe 1/2013

Einloggen, um Zugang zu erhalten

Abstract

Bilateral risk-reducing salpingo-oophorectomy (RRSO) has been shown to significantly reduce the risk of ovarian cancer. This study assessed factors predicting uptake of RRSO. Women participating in a large multiple-case breast cancer family cohort study who were at increased risk for ovarian and fallopian tube cancer (i.e. BRCA1 or BRCA2 mutation carrier or family history including at least one first- or second-degree relative with ovarian or fallopian tube cancer), with no personal history of cancer and with at least one ovary in situ at cohort enrolment, were eligible for this study. Women who knew they did not carry the BRCA1 or BRCA2 mutation segregating in their family (true negatives) were excluded. Sociodemographic, biological and psychosocial factors, including cancer-specific anxiety, perceived ovarian cancer risk, optimism and social support, were assessed using self-administered questionnaires and interviews at cohort enrolment. RRSO uptake was self-reported every three years during systematic follow-up. Of 2,859 women, 571 were eligible. Mean age was 43.3 years; 62 women (10.9 %) had RRSO a median of two years after cohort entry. Factors predicting RRSO were: being parous (OR 3.3, p = 0.015); knowing one’s mutation positive status (OR 2.9, p < 0.001) and having a mother and/or sister who died from ovarian cancer (OR 2.5, p = 0.013). Psychological variables measured at cohort entry were not associated with RRSO. These results suggest that women at high risk for ovarian cancer make decisions about RRSO based on risk and individual socio-demographic characteristics, rather than in response to psychological factors such as anxiety.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Antoniou A et al (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72(5):1117–1130PubMedCrossRef Antoniou A et al (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72(5):1117–1130PubMedCrossRef
2.
Zurück zum Zitat Rebbeck T, Kauff N, Domchek S (2009) Meta-analysis of risk reduction estimates associated with risk-reducing salpingooophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst 101:80–87PubMedCrossRef Rebbeck T, Kauff N, Domchek S (2009) Meta-analysis of risk reduction estimates associated with risk-reducing salpingooophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst 101:80–87PubMedCrossRef
3.
Zurück zum Zitat Cancer Australia, Recommendations for management of women at high risk for ovarian cancer September 2011, Cancer Australia: Canberra Cancer Australia, Recommendations for management of women at high risk for ovarian cancer September 2011, Cancer Australia: Canberra
4.
Zurück zum Zitat Debeau L (2008) The cell of origin of ovarian epithelial tumours. Lancet 9:1191–1197CrossRef Debeau L (2008) The cell of origin of ovarian epithelial tumours. Lancet 9:1191–1197CrossRef
5.
Zurück zum Zitat Antill Y et al (2006) Risk-reducing surgery in women with familial susceptibility for breast and/or ovarian cancer. Eur J Cancer 42(5):621–628PubMedCrossRef Antill Y et al (2006) Risk-reducing surgery in women with familial susceptibility for breast and/or ovarian cancer. Eur J Cancer 42(5):621–628PubMedCrossRef
6.
Zurück zum Zitat Julian-Reynier C et al (2010) Time to prophylactic surgery in BRCA1/2 carriers depends on psychological and other characteristics. Genet Med 12(12):801–807PubMedCrossRef Julian-Reynier C et al (2010) Time to prophylactic surgery in BRCA1/2 carriers depends on psychological and other characteristics. Genet Med 12(12):801–807PubMedCrossRef
7.
Zurück zum Zitat Metcalfe K et al (2008) Family history as a predictor of uptake of cancer preventive procedures by women with a BRCA1 or BRCA2 mutation. Clin Genet 73(5):474–479PubMedCrossRef Metcalfe K et al (2008) Family history as a predictor of uptake of cancer preventive procedures by women with a BRCA1 or BRCA2 mutation. Clin Genet 73(5):474–479PubMedCrossRef
8.
Zurück zum Zitat Madalinska JB et al (2006) The impact of hormone replacement therapy on menopausal symptoms in younger high-risk women after prophylactic salpingo-oophorectomy. J Clin Oncol 24(22):3576–3582PubMedCrossRef Madalinska JB et al (2006) The impact of hormone replacement therapy on menopausal symptoms in younger high-risk women after prophylactic salpingo-oophorectomy. J Clin Oncol 24(22):3576–3582PubMedCrossRef
9.
Zurück zum Zitat Evans D et al (2009) Uptake of risk-reducing surgery in unaffected women at high risk of breast and ovarian cancer is risk, age, and time dependent. Cancer Epidemiol Biomark Prev 18:2318–2324CrossRef Evans D et al (2009) Uptake of risk-reducing surgery in unaffected women at high risk of breast and ovarian cancer is risk, age, and time dependent. Cancer Epidemiol Biomark Prev 18:2318–2324CrossRef
10.
Zurück zum Zitat Scheier MF, Carver CS (1985) Optimism, coping and health: assessment and implications of generalized outcome expectancies. Health Psychol 4(3):219–247PubMedCrossRef Scheier MF, Carver CS (1985) Optimism, coping and health: assessment and implications of generalized outcome expectancies. Health Psychol 4(3):219–247PubMedCrossRef
11.
Zurück zum Zitat Broadhead W et al (1988) The Duke-UNC functional social support questionnaire. Med Care 26(7):709–722PubMedCrossRef Broadhead W et al (1988) The Duke-UNC functional social support questionnaire. Med Care 26(7):709–722PubMedCrossRef
12.
Zurück zum Zitat Schwartz MD et al (2003) Bilateral prophylactic oophorectomy and ovarian cancer screening following BRCA1/BRCA2 mutation testing. J Clin Oncol 21(21):4034–4041PubMedCrossRef Schwartz MD et al (2003) Bilateral prophylactic oophorectomy and ovarian cancer screening following BRCA1/BRCA2 mutation testing. J Clin Oncol 21(21):4034–4041PubMedCrossRef
13.
Zurück zum Zitat Hatcher MB, Fallowfield L, A’Hern R (2001) The psychological impact of prophylactic mastectomy: prospective study using questionnaires and semistructured interviews. Br Med J 322(322):76–79CrossRef Hatcher MB, Fallowfield L, A’Hern R (2001) The psychological impact of prophylactic mastectomy: prospective study using questionnaires and semistructured interviews. Br Med J 322(322):76–79CrossRef
14.
Zurück zum Zitat Phillips K-A et al (2005) Predictors of participation in clinical and psychosocial follow up of the kConFab breast cancer family study. Fam Cancer 4(2):105–113PubMedCrossRef Phillips K-A et al (2005) Predictors of participation in clinical and psychosocial follow up of the kConFab breast cancer family study. Fam Cancer 4(2):105–113PubMedCrossRef
15.
Zurück zum Zitat Mann G et al (2006) Analysis of cancer risk and BRCA1 and BRCA2 mutation prevalence in the kConFab familial breast cancer resource. Breast Cancer Res 8:R12PubMedCrossRef Mann G et al (2006) Analysis of cancer risk and BRCA1 and BRCA2 mutation prevalence in the kConFab familial breast cancer resource. Breast Cancer Res 8:R12PubMedCrossRef
16.
Zurück zum Zitat Antoniou A et al (2008) The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. Br J Cancer 98:1457–1466PubMedCrossRef Antoniou A et al (2008) The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. Br J Cancer 98:1457–1466PubMedCrossRef
17.
Zurück zum Zitat Horowitz M, Wilner N, Alvarez W (1979) Impact of events scale: a measure of subjective stress. Psychosom Med 41:209–218PubMed Horowitz M, Wilner N, Alvarez W (1979) Impact of events scale: a measure of subjective stress. Psychosom Med 41:209–218PubMed
18.
Zurück zum Zitat Hosmer D, Lemeshow S (2000) Applied logistic regression, 2nd edn. Wiley, TorontoCrossRef Hosmer D, Lemeshow S (2000) Applied logistic regression, 2nd edn. Wiley, TorontoCrossRef
19.
Zurück zum Zitat Cohen J (1988) Statistical power analysis for the behavioural sciences, 2nd edn. Academic Press, New York Cohen J (1988) Statistical power analysis for the behavioural sciences, 2nd edn. Academic Press, New York
20.
Zurück zum Zitat Frost M (2002) Symposium on clinical significance of quality of life measures in cancer patients. Mayo Proceedings 77: 488–494 Frost M (2002) Symposium on clinical significance of quality of life measures in cancer patients. Mayo Proceedings 77: 488–494
21.
Zurück zum Zitat Miller S et al (2010) New strategies in risk-reducing salpingo-oophorectomy: uptake and experience of women at high risk of ovarian cancer who are considering risk-reducing salpingo-oophorectomy. Clin Cancer Res 16(21):5094–5106PubMedCrossRef Miller S et al (2010) New strategies in risk-reducing salpingo-oophorectomy: uptake and experience of women at high risk of ovarian cancer who are considering risk-reducing salpingo-oophorectomy. Clin Cancer Res 16(21):5094–5106PubMedCrossRef
22.
Zurück zum Zitat Meiser B et al (1999) Attitudes to prophylactic oophorectomy and screening utilization in women at increased risk of developing hereditary breast/ovarian cancer. Gynecol Oncol 75:122–129PubMedCrossRef Meiser B et al (1999) Attitudes to prophylactic oophorectomy and screening utilization in women at increased risk of developing hereditary breast/ovarian cancer. Gynecol Oncol 75:122–129PubMedCrossRef
23.
Zurück zum Zitat Meiser B et al (2003) Attitudes to prophylactic strategies in Australian women at increased risk for breast cancer. J Women’s Health 12(8):769–778CrossRef Meiser B et al (2003) Attitudes to prophylactic strategies in Australian women at increased risk for breast cancer. J Women’s Health 12(8):769–778CrossRef
24.
Zurück zum Zitat Meiser B et al (2000) Intention to undergo prophylactic mastectomy in women at increased risk of developing hereditary breast cancer. J Clin Oncol 18(11):2250–2257PubMed Meiser B et al (2000) Intention to undergo prophylactic mastectomy in women at increased risk of developing hereditary breast cancer. J Clin Oncol 18(11):2250–2257PubMed
25.
Zurück zum Zitat McQuirter M et al (2010) Decision-making process of women carrying a BRCA1 or BRCA2 mutation who have chosen prophylactic mastectomy. Oncol Nurs Forum 37(3):313–320PubMedCrossRef McQuirter M et al (2010) Decision-making process of women carrying a BRCA1 or BRCA2 mutation who have chosen prophylactic mastectomy. Oncol Nurs Forum 37(3):313–320PubMedCrossRef
26.
Zurück zum Zitat Taylor S (1983) Adjustment to threatening events: a theory of cognitive adaptation. Am Psychol 38(11):1162–1174CrossRef Taylor S (1983) Adjustment to threatening events: a theory of cognitive adaptation. Am Psychol 38(11):1162–1174CrossRef
27.
28.
Zurück zum Zitat Bradbury AR et al (2008) Uptake and timing of bilateral prophylactic salpingo-oophorectomy among BRCA1 and BRCA2 mutation carriers. Genet Med 10(3):161–166PubMedCrossRef Bradbury AR et al (2008) Uptake and timing of bilateral prophylactic salpingo-oophorectomy among BRCA1 and BRCA2 mutation carriers. Genet Med 10(3):161–166PubMedCrossRef
29.
Zurück zum Zitat Meiser B (2005) Psychological impact of genetic testing for cancer susceptibility: an update of the literature. Psycho-Oncology 14:1060–1074PubMedCrossRef Meiser B (2005) Psychological impact of genetic testing for cancer susceptibility: an update of the literature. Psycho-Oncology 14:1060–1074PubMedCrossRef
30.
Zurück zum Zitat Meiser B et al (2007) International perspectives on genetic counseling and testing for breast cancer risk. Breast Dis 27:109–125 Meiser B et al (2007) International perspectives on genetic counseling and testing for breast cancer risk. Breast Dis 27:109–125
31.
Zurück zum Zitat Julian-Reynier C et al (2000) Physicians’ attitudes towards mammography and prophylactic surgery for hereditary breast/ovarian cancer risk and subsequently published guidelines. Eur J Hum Genet 8:204–208PubMedCrossRef Julian-Reynier C et al (2000) Physicians’ attitudes towards mammography and prophylactic surgery for hereditary breast/ovarian cancer risk and subsequently published guidelines. Eur J Hum Genet 8:204–208PubMedCrossRef
32.
Zurück zum Zitat Julian-Reynier CM et al (2001) Women’s attitudes toward preventive strategies for hereditary breast or ovarian carcinoma differ from one country to another: differences among English, French, and Canadian women. Cancer 92(4):959–968PubMedCrossRef Julian-Reynier CM et al (2001) Women’s attitudes toward preventive strategies for hereditary breast or ovarian carcinoma differ from one country to another: differences among English, French, and Canadian women. Cancer 92(4):959–968PubMedCrossRef
Metadaten
Titel
Psychosocial factors and uptake of risk-reducing salpingo-oophorectomy in women at high risk for ovarian cancer
verfasst von
Bettina Meiser
Melanie A. Price
Phyllis N. Butow
Janan Karatas
Judy Wilson
Louise Heiniger
Brandi Baylock
Margaret Charles
Sue-Anne McLachlan
Kelly-Anne Phillips
Publikationsdatum
01.03.2013
Verlag
Springer Netherlands
Erschienen in
Familial Cancer / Ausgabe 1/2013
Print ISSN: 1389-9600
Elektronische ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-012-9585-8

Weitere Artikel der Ausgabe 1/2013

Familial Cancer 1/2013 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.